載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.99
+US$0.0081 · +0.82%
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
前收盤價
US$0.99
+US$0.0081 · +0.82%
盤中時間採用ET。市場資料可能有所延遲。
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$0.99
52週區間
目前US$0.99
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
54
多空交錯
風險
67
高風險
動能
27
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$0.99
52週區間
目前US$0.99
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 32萬 USD | — | — | — | — |
| 銷貨成本 | — | — | — | 12萬 USD | 10.6萬 USD |
| 毛利 | 32萬 USD | — | — | −12萬 USD | −10.6萬 USD |
| 研究與開發 | 660.1萬 USD | 609.6萬 USD | 710.3萬 USD | 693萬 USD | 1419.6萬 USD |
| 銷售、一般及管理費用 | 632.4萬 USD | 1144.2萬 USD | 1002.6萬 USD | 996.2萬 USD | 1236萬 USD |
| 營業費用 | 1292.5萬 USD | 2724.1萬 USD | 1712.9萬 USD | 3446.3萬 USD | 2655.6萬 USD |
| 利息收入 | 80.1萬 USD | 53.3萬 USD | 2.2萬 USD | 3萬 USD | — |
| 利息支出 | 18.5萬 USD | 65.3萬 USD | 49.8萬 USD | 22.3萬 USD | 64萬 USD |
| 折舊和攤銷 | −1.3萬 USD | 9000 USD | 3.7萬 USD | 6萬 USD | 10.6萬 USD |
| 營業利益 | −1260.5萬 USD | −2724.1萬 USD | −1712.9萬 USD | −3446.3萬 USD | −2655.6萬 USD |
| 淨利 | −1123.1萬 USD | −2451.5萬 USD | −1190.1萬 USD | −1605.8萬 USD | −2664.8萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年9月11日 | 1:30 | — | — |
股票分割 | 2024年4月9日 | 1:20 | — | — |
股票分割 | 2023年6月29日 | 1:40 | — | — |
股票分割 | 2023年3月27日 | 1:35 | — | — |
已生效 2024年9月11日
1:30
已生效 2024年4月9日
1:20
已生效 2023年6月29日
1:40
已生效 2023年3月27日
1:35
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
